Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.56 |
| ▸ | WNT3A | P56704 | 2/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5954679 | 0.98 | THRA (0.64) | THRATHRBCES2CES1CTNNB1 | |
| SCHEMBL9509517 | 0.85 | THRA (0.60) | THRATHRBKMT2AEGFR | |
| SCHEMBL664955 | 0.84 | CES2 (0.61) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL22624890 | 0.83 | CYP1A2 (0.68) | THRATHRBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL19984838 | 0.82 | CES2 (0.62) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL8269548 | 0.82 | HSD11B1 (0.64) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL4637827 | 0.82 | CES2 (0.62) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL4722288 | 0.81 | ALDH1A1 (0.69) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL31557732 | 0.81 | CES2 (0.61) | CES2CES1CTNNB1WNT3APARP1 | |
| SCHEMBL30416831 | 0.81 | ALDH1A1 (0.69) | CES2CES1CTNNB1WNT3APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730705-B2 | Small molecule CMKLR1 antagonists in inflammatory disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730705-B2 | Small molecule CMKLR1 antagonists in inflammatory disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200345661-A1 | SMALL MOLECULE CMKLR1 ANTAGONISTS IN INFLAMMATORY DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-11-05 | — | — | US | disclosed |
| US-20090253936-A1 | Reacting 3-dimethylamino-1-(3-methoxyphenyl)-propan-1-one with an alpha , beta -unsaturated ketone to form 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione andand cyclizing the 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione; stereoisomers; catalyst selectivity; analgesics | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253936-A1 | Reacting 3-dimethylamino-1-(3-methoxyphenyl)-propan-1-one with an alpha , beta -unsaturated ketone to form 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione andand cyclizing the 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione; stereoisomers; catalyst selectivity; analgesics | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253936-A1 | Reacting 3-dimethylamino-1-(3-methoxyphenyl)-propan-1-one with an alpha , beta -unsaturated ketone to form 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione andand cyclizing the 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione; stereoisomers; catalyst selectivity; analgesics | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009106336-A1 | METHOD FOR THE PRODUCTION OF (1RS,3RS,6RS)-6-DIMETHYL AMINO ETHYL-1-(3-METHOXY PHENYL)-CYCLOHEXANE-1,3-DIOL | Grünenthal GmbH (DE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106336-A1 | METHOD FOR THE PRODUCTION OF (1RS,3RS,6RS)-6-DIMETHYL AMINO ETHYL-1-(3-METHOXY PHENYL)-CYCLOHEXANE-1,3-DIOL | Grünenthal GmbH (DE) | 2009-09-03 | — | — | WO | disclosed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2007019933-A1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| US-20060058374-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040077529-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077529-A1 | Urotensin II receptor agents | UTS2R, PLAUR, GPR17 | THRA 663/4885THRB 835/4885CES2 1611/4885 |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MET, FLT3, ERBB3 | THRA 129/4885THRB 113/4885CES2 1839/4885 |
| US-20090253936-A1 | Reacting 3-dimethylamino-1-(3-methoxyphenyl)-propan-1-one with an alpha , beta -unsaturated ketone to form 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione andand cyclizing the 2-dimethylaminomethyl-1-(3-methoxyphenyl)hexane-1,5-dione; stereoisomers; catalyst selectivity; analgesics | OPRD1, OPRK1, OPRM1 | THRA 636/4885THRB 1639/4885CES2 498/4885 |
| US-20200345661-A1 | SMALL MOLECULE CMKLR1 ANTAGONISTS IN INFLAMMATORY DISEASE | CMKLR1, CMKLR2, IL1RN | THRA 623/4885THRB 1445/4885CES2 3886/4885 |
| US-20060058374-A1 | Urotensin II receptor agents | UTS2R, PLAUR, SCTR | THRA 650/4885THRB 751/4885CES2 1700/4885 |
| US-11730705-B2 | Small molecule CMKLR1 antagonists in inflammatory disease | CMKLR1, CMKLR2, IL1RN | THRA 623/4885THRB 1445/4885CES2 3886/4885 |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | THRA 281/4885THRB 319/4885CES2 4753/4885 |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | THRA 286/4885THRB 327/4885CES2 4768/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | THRA 378/4885THRB 401/4885CES2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.